Literature DB >> 16778713

Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.

Frieder Kees1, Michael Bucher, Frank Schweda, Harald Gschaidmeier, Juergen Burhenne, Gerd Mikus, Lothar Faerber.   

Abstract

The aim of this study was to compare the bioavailability of cyclosporine (CyA) from the generic dispersion formulation Cicloral (CIC) with the microemulsion formulation Neoral (NEO) and the original Sandimmune (SIM) capsules after single doses of 100, 300, or 600 mg of drug, respectively. The study was performed according to an open 3-period cross-over design with 12 young healthy male volunteers for each dosage. The concentrations of CyA and its main metabolites were determined by high performance liquid chromatography in whole blood and urine up to 48 hours postdosing. Peak concentrations and area under the time-concentration curve were greater for the NEO and CIC formulations compared with SIM, and the mean bioavailability of CIC was significantly (P<0.05) lower compared with NEO. The bioavailability of SIM compared with NEO was 54% to 71%, in agreement with previous results. Bioequivalence was not demonstrated between CIC (test) and NEO (reference) as the 90% confidence intervals were outside the 80% to 125% guidelines based on log-transformed AUCs, and were 75.2% to 87.7% at 100 mg, 79.2% to 91.8% at 300 mg, and 76.6% to 94.5% at 600 mg doses. The respective values for Cmax were 78.9% to 94.6%, 80.7% to 95.0%, and 71.4% to 84.1%. A good correlation was demonstrated between the urinary recovery of CyA and the AUC4. Therefore, the urinary recovery of CyA may be helpful as a surrogate parameter for the systemic exposure of patients to CyA. Whereas the relative amount of hydroxylated metabolites (AM1, AM9, AM1c) was similar for all formulations and doses, the urinary recovery of the N-demethylated metabolite AM4N decreased with increasing dose indicating saturable metabolism. No relationship could be demonstrated between CYP3A activity using dextromethorphan as a probe for the metabolic clearance of CyA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778713     DOI: 10.1097/01.ftd.0000211804.89440.74

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.

Authors:  Michael Gertz; Catherine M Cartwright; Michael J Hobbs; Kathryn E Kenworthy; Malcolm Rowland; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2012-11-22       Impact factor: 4.200

2.  Neoimmun versus Neoral: a bioequivalence study in healthy volunteers and influence of a fat-rich meal on the bioavailability of Neoimmun.

Authors:  F Kees; M Bucher; F Schweda; H Gschaidmeier; L Faerber; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-15       Impact factor: 3.195

3.  Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring.

Authors:  Sonja E Zapke; Stefan Willmann; Scott-Oliver Grebe; Kristin Menke; Petra A Thürmann; Sven Schmiedl
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

Review 4.  Bioavailability, Efficacy and Safety of Generic Immunosuppressive Drugs for Kidney Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Evangelos Tsipotis; Navin R Gupta; Gowri Raman; Elias Zintzaras; Bertrand L Jaber
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 4.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.